Hematologic malignancies represent approximately 6.5% of adult and 70% of pediatric cancers. The development of cellular immune-based therapy, such as CD19-CAR-T cell therapy has been a significant advance in the treatment of relapsed and refractory aggressive B cell malignancies like acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL). This modality has remarkably improved outcomes in both pediatric and adult disease. This treatment has come with unique side effects, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require training specialized clinical training, and skills to manage. Basic, translational, and clinical research continue to develop strategies to expand the application of this cell-based modality to other targets, increase efficacy, develop other immune effector cells, expand to other hematologic malignancies and improve tolerability and reduce toxicities.
Although very powerful in terms of outcome, the use of these treatments has not found a definite role in clinical practice since currently available data show a large variety in the use of these treatments, first-, second-, or subsequent-line therapy and the need for further consolidation therapy. The aim of this Research Topic is to review the current state of these treatments in terms of indications, outcomes, and side effects, and toxicities.
1. Describe current cell-based targeted therapy modalities available to treat pediatric and adult hematologic malignancies.
2. Describe pre-clinical, translational, and early clinical strategies to increase efficacy and expand the application of cellular-based targeted therapy for pediatric and adult hematologic malignancies.
3. Describe and review the side effects of cell-based immune therapy to standardize the identification, grading, and management strategies.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Hematologic malignancies represent approximately 6.5% of adult and 70% of pediatric cancers. The development of cellular immune-based therapy, such as CD19-CAR-T cell therapy has been a significant advance in the treatment of relapsed and refractory aggressive B cell malignancies like acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL). This modality has remarkably improved outcomes in both pediatric and adult disease. This treatment has come with unique side effects, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require training specialized clinical training, and skills to manage. Basic, translational, and clinical research continue to develop strategies to expand the application of this cell-based modality to other targets, increase efficacy, develop other immune effector cells, expand to other hematologic malignancies and improve tolerability and reduce toxicities.
Although very powerful in terms of outcome, the use of these treatments has not found a definite role in clinical practice since currently available data show a large variety in the use of these treatments, first-, second-, or subsequent-line therapy and the need for further consolidation therapy. The aim of this Research Topic is to review the current state of these treatments in terms of indications, outcomes, and side effects, and toxicities.
1. Describe current cell-based targeted therapy modalities available to treat pediatric and adult hematologic malignancies.
2. Describe pre-clinical, translational, and early clinical strategies to increase efficacy and expand the application of cellular-based targeted therapy for pediatric and adult hematologic malignancies.
3. Describe and review the side effects of cell-based immune therapy to standardize the identification, grading, and management strategies.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.